Steven Lichtman
Stock Analyst at Oppenheimer
(4.41)
# 384
Out of 4,749 analysts
67
Total ratings
53.19%
Success rate
21.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $86.83 | +20.93% | 8 | Oct 25, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $109.48 | +23.31% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $5.79 | +107.25% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $91.09 | +20.76% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $90.82 | +3.50% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $33.87 | +91.91% | 8 | Aug 6, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $47 → $58 | $37.06 | +56.50% | 1 | Jun 10, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $10.51 | +4.66% | 5 | May 9, 2024 | |
| ANGO AngioDynamics | Upgrades: Outperform | $12 | $11.41 | +5.17% | 2 | Apr 5, 2024 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $82 → $87 | $108.88 | -20.10% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $58 → $68 | $102.36 | -33.57% | 2 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $1.28 | +173.44% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $300 → $275 | $278.38 | -1.21% | 5 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $391.29 | -26.40% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $156.44 | -32.88% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $24.19 | +520.09% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $96.55 | -11.96% | 3 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.58 | - | 2 | Apr 12, 2017 |
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $86.83
Upside: +20.93%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $109.48
Upside: +23.31%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $5.79
Upside: +107.25%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $91.09
Upside: +20.76%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $90.82
Upside: +3.50%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $33.87
Upside: +91.91%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47 → $58
Current: $37.06
Upside: +56.50%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $10.51
Upside: +4.66%
AngioDynamics
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $11.41
Upside: +5.17%
Merit Medical Systems
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $108.88
Upside: -20.10%
Feb 1, 2024
Maintains: Perform
Price Target: $58 → $68
Current: $102.36
Upside: -33.57%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $1.28
Upside: +173.44%
Jan 31, 2022
Upgrades: Outperform
Price Target: $300 → $275
Current: $278.38
Upside: -1.21%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $391.29
Upside: -26.40%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $156.44
Upside: -32.88%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $24.19
Upside: +520.09%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $96.55
Upside: -11.96%
Apr 12, 2017
Downgrades: Perform
Price Target: n/a
Current: $0.58
Upside: -